SCHEMBL3274410

SCHEMBL3274410

CCOC(=O)CNC(=O)c1ccc(S(=O)(=O)Nc2ccccc2Oc2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1H O95180 3/20 0.58
CACNA1B Q00975 3/20 0.58
NPC1 O15118 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
RAB9A P51151 1/20 0.52
TDP1 Q9NUW8 3/20 0.50
HTT P42858 3/20 0.47
POLB P06746 2/20 0.46
KCNA5 P22460 1/20 0.46
CCR2 P41597 2/20 0.45
LMNA P02545 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
KDM4E B2RXH2 1/20 0.45
GAA P10253 1/20 0.45
ALDH1A1 P00352 1/20 0.45
TP53 P04637 1/20 0.45
HPGD P15428 1/20 0.45
MAPK14 Q16539 1/20 0.44
CCR1 P32246 1/20 0.43
PTGDR2 Q9Y5Y4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3274521 0.93 CACNA1H (0.53) CACNA1HCACNA1BNPC1SMN1; SMN2RAB9A
SCHEMBL3273893 0.92 TDP1 (0.49) CACNA1HCACNA1BNPC1SMN1; SMN2RAB9A
SCHEMBL3045528 0.91 TDP1 (0.54) CACNA1HCACNA1BNPC1SMN1; SMN2RAB9A
SCHEMBL3281479 0.89 CACNA1H (0.59) CACNA1HCACNA1BTDP1KCNA5CCR2
SCHEMBL3275031 0.84 MRGPRX1 (0.49) NPC1SMN1; SMN2RAB9ACCR2LMNA
SCHEMBL3050536 0.82 CACNA1H (0.62) CACNA1HCACNA1BTDP1CCR2CCR1
SCHEMBL3052650 0.81 CCR2 (0.48) CCR2LMNAKDM4EALDH1A1HPGD
SCHEMBL3052348 0.81 CCR2 (0.45) NPC1SMN1; SMN2RAB9ACCR2ALDH1A1
SCHEMBL3280640 0.80 CACNA1H (0.52) CACNA1HCACNA1BNPC1SMN1; SMN2RAB9A
SCHEMBL3275037 0.80 TDP1 (0.50) CACNA1HCACNA1BTDP1CCR2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2076491-B1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-07-17 EP disclosed
US-8481527-B2 Benzamide derivatives as bradykinin antagonists RICHTER GEDEON NYRT. (HU) 2013-07-09 US disclosed
US-20100087423-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-04-08 US disclosed
EP-2076491-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS Richter Gedeon NYRT (HU) 2009-07-08 EP disclosed
WO-2008068540-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087423-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS BDKRB1, BDKRB2, HRH1 CACNA1H 997/4885CACNA1B 915/4885NPC1 2456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.